Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

Objectives: NTRK fusions result in constitutively active oncogenic TRK proteins responsible for ∼ 0.2 % of non-small cell lung cancer (NSCLC) cases. Approximately 40 % of patients with advanced NSCLC develop CNS metastases; therefore, treatments with intracranial (IC) efficacy are needed. In an integrated analysis of three phase I/II studies (ALKA-372–001: EudraCT 2012–000148–88; STARTRK-1: NCT02097810; STARTRK-2: NCT02568267), entrectinib, a potent, CNS-active, TRK inhibitor, demonstrated efficacy in patients with NTRK fusion-positive (fp) NSCLC (objective response rate [ORR]: 64.5 %; 2 August 2021 data cut-off). We present updated data for this cohort. Materials and methods: Eligible patients were ≥ 18 years with locally advanced/metastatic, NTRK-fp NSCLC with ≥ 12 months of follow-up. Tumor responses were assessed by blinded independent central review (BICR) per RECIST v1.1 at Week 4 and every eight weeks thereafter. Co-primary endpoints: ORR; duration of response (DoR). Secondary endpoints included progression-free survival (PFS); overall survival (OS); IC efficacy; safety. Enrolment cut-off: 2 July 2021; data cut-off: 2 August 2022. Results: The efficacy-evaluable population included 51 patients with NTRK-fp NSCLC. Median age was 60.0 years (range 22–88); 20 patients (39.2 %) had investigator-assessed baseline CNS metastases. Median survival follow–up was 26.3 months (95 % CI 21.0–34.1). ORR was 62.7 % (95 % CI 48.1–75.9), with six complete and 26 partial responses. Median DoR and PFS were 27.3 months (95 % CI 19.9–30.9) and 28.0 months (95 % CI 15.7–30.4), respectively. Median OS was 41.5 months. In patients with BICR-assessed baseline CNS metastases, IC-ORR was 64.3 % (n = 9/14; 95 % CI 35.1–87.2), including seven complete responders, and IC-DoR was 55.7 months. In the safety–evaluable population (n = 55), most treatment-related adverse events were grade 1/2; no treatment-related deaths were reported. Conclusion: Entrectinib has continued to demonstrate deep and durable systemic and IC responses in patients with NTRK-fp NSCLC.